

Joint Working EXECUTIVE SUMMARY

Published on www.astrazeneca.co.uk

Joint Working between AstraZeneca UK Ltd and FEDERATION OF FAMILY PRACTICES ARDS C.I.C.

Document Number 350-1-ES

Date of Preparation Aug 2025

Project title	CARDS Improving COPD outcomes in ARDS
Aims and Objectives	<p>Project Aim is to improve management of uncontrolled COPD with Cardiovascular risk and reduce carbon footprint of COPD medication.</p> <p>Project objectives:</p> <ol style="list-style-type: none">1. Identification and risk stratification of uncontrolled COPD patients suitable for review2. Embed guideline directed care – GOLD COPD guidelines3. Embed COPD template4. Optimisation of uncontrolled COPD patients both pharmacologically and non-pharmacologically5. Reduce carbon footprint of COPD medication
Anticipated benefits	<p>Patient benefits:</p> <p>Optimisation of COPD management pharmacologically</p> <p>Optimisation of COPD management non-pharmacologically</p> <p>Appropriate onward referral to secondary care</p> <p>NHS benefits :</p> <p>Implementation of GOLD COPD guidelines</p> <p>Identification and review of uncontrolled COPD patients</p> <p>Reduction in carbon footprint of COPD medication</p> <p>Embedding of COPD template</p> <p>AstraZeneca benefits:</p> <p>Example of a successful partnership</p> <p>Implementation of GOLD guidelines</p> <p>Aligned to AZ medical missions</p> <p>May increase the use of AZ medicines/inhalers in line with local/national guidelines</p> <p>May increase prescribing of AZ medicines/inhalers in line with local/national guidelines, however, this Project is not reliant upon the prescribing of AstraZeneca medicines, and all prescribing decisions shall be at the independent discretion of the treating clinician</p>

Timeline	The project will commence on the September 2025 and will continue for a duration of 16 months.
References	[References]